A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Affiliations

• ¹ Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
• ² Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.
• ³ Washington University School of Medicine, Siteman Cancer Center, St Louis, MO.
• ⁴ Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
• ⁵ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
• ⁶ Department of Pathology, The Ohio State University, Columbus, OH.
• ⁷ Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß.
• ⁸ Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
• ⁹ Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA. william.g.blum@emory.edu.